Cytek Biosciences (CTKB) Receivables - Net (2020 - 2025)
Cytek Biosciences (CTKB) has disclosed Receivables - Net for 6 consecutive years, with $62.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 3.17% year-over-year to $62.5 million, compared with a TTM value of $62.5 million through Dec 2025, up 3.17%, and an annual FY2025 reading of $62.5 million, up 3.17% over the prior year.
- Receivables - Net was $62.5 million for Q4 2025 at Cytek Biosciences, up from $56.6 million in the prior quarter.
- Across five years, Receivables - Net topped out at $62.5 million in Q4 2025 and bottomed at $24.0 million in Q2 2021.
- Average Receivables - Net over 5 years is $46.4 million, with a median of $49.6 million recorded in 2023.
- The sharpest move saw Receivables - Net skyrocketed 75.16% in 2021, then decreased 10.04% in 2024.
- Year by year, Receivables - Net stood at $29.8 million in 2021, then surged by 64.19% to $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then rose by 8.33% to $60.6 million in 2024, then grew by 3.17% to $62.5 million in 2025.
- Business Quant data shows Receivables - Net for CTKB at $62.5 million in Q4 2025, $56.6 million in Q3 2025, and $56.2 million in Q2 2025.